Mayo Clinic study links antioxidants to lowered follicular lymphoma risk

An exhaustive study by the Mayo Clinic involving 35,159 Iowa women aged 55-69 beginning in 1986 and continuing through 2005 examined the role of antioxidant nutrients found in fruits, vegetables and other foods in raising or lowering the risk factor for developing follicular lymphoma and diffuse large B-cell lymphoma (DLBCL).

In brief, researchers concluded that:

- Greater intake of total fruits and vegetables, yellow/orange and cruciferous vegetables, broccoli and apple juice/cider are associated with a lower NHL risk, although this was only observed for follicular lymphoma, not in DLBCL.

- No strong associations were found for other antioxidant-rich foods, including whole grains, chocolate, tea or nuts.

- And no associations were found with multivitamin use or supplemental intake of vitamins C, E, selenium, zinc, copper or manganese.

Read the PubMed abstract here.

By Ross Bonander

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap